Description
4-Aminobenzoic acid hydrazide (4-ABAH) is an irreversible inhibitor of myeloperoxidase (MPO; IC
50 = 0.3 μM). It reduces the production of hypochlorous acid (HOCl) induced by opsonized zymosan or phorbol 12-myristate 13-acetate (PMA; ) in isolated human neutrophils with IC
50 values of 16 and 2.2 μM, respectively. 4-ABAH inhibits PMA-induced formation of neutrophil extracellular traps (NETs) in the same cells. It reduces infarct volume and the severity of neurological deficits, as well as increases survival, in a mouse model of cerebral ischemia induced by transient middle cerebral artery occlusion (MCAO) when administered at a dose of 40 mg/kg twice per day.
Chemical Properties
White or beige crystals or powder
Uses
4-Aminobenzoic hydrazide can be used as a reactant to synthesize:
- Acylhydrazone Schiff base ligand by condensation reaction with 2-acetylpyridine.
- Oligomeric transition metal complexes applicable in the fabrication of organic-inorganic hybrid devices with efficient electrical and photoelectrical properties.
- Oxovanadium(IV)-hydrazide complex as a potential radical scavenger.
Uses
4-Aminobenzhydrazide has an important role in the peroxidation activity of MPO. It is also used in enzyme preparations and in cell cultures.
References
[1] A J KETTLE. Inhibition of myeloperoxidase by benzoic acid hydrazides.[J]. Biochemical Journal, 1995, 308 ( Pt 2): 559-563. DOI:
10.1042/bj3080559[2] SHUICHIRO NAKABO. Activated neutrophil carbamylates albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis.[J]. Modern Rheumatology, 2020, 30 2: 345-349. DOI:
10.1080/14397595.2019.1583819[3] REZA FORGHANI. Myeloperoxidase propagates damage and is a potential therapeutic target for subacute stroke.[J]. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism, 2015: 485-493. DOI:
10.1038/jcbfm.2014.222[4] RINA KIM. Ferroptosis of tumour neutrophils causes immune suppression in cancer[J]. Nature, 2022, 612 7939: 338-346. DOI:
10.1038/s41586-022-05443-0
